Effect of clinical treatments for metabolic syndrome on albuminuria: a systematic review protocol
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introduction: Metabolic syndrome (MetS) predicts cardiovascular disease, and patients with this condition and type 2 diabetes have increased albuminuria, significantly impacting cardiovascular mortality and kidney disease progression. A considerable number of interventions to control MetS exist and are considered efficient, including the use of medication and changes in lifestyle. However, which approaches are effective in controlling albuminuria remains unclear. This systematic review protocol aims to map in the available literature whether lifestyle, medication, and surgical intervention for MetS have an impact on reducing albuminuria in adult patients. Methods: The Joanna Briggs Institute methodology for systematic reviews will be followed. Cochrane Database of Systematic Reviews, Scopus, Embase, and MEDLINE/PubMed databases will be used. For the Gray Literature, the DART-Europe E-theses Portal. There will be no language restriction. Studies written after 2009 will be included due to the consensus and definition of metabolic syndrome. This review will include studies considering pharmacological and non-pharmacological treatments for controlling albuminuria in patients with MetS. Studies where MetS is described in children and adolescents, animals, pregnant women, and patients with type 1 diabetes will be excluded. First, the selection will be based on reading the title and summary of the texts retrieved in the search strategy, followed by reading the relevant texts in full by two reviewers. After the selection of the studies, the extraction of the data, analysis, and synthesis will be conducted according to the JBI methodology.
Detalhes do artigo
Os autores mantêm os direitos autorais e concedem ao HSJ o direito de primeira publicação. A partir de 2024, as publicações serão licenciadas sob a Attribution 4.0 International 
, permitindo seu compartilhamento, reconhecendo a autoria e publicação inicial nesta revista.
Os autores estão autorizados a assumir contratos adicionais separadamente para distribuição não exclusiva da versão do trabalho publicada nesta revista (por exemplo, publicação em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
Os autores são incentivados a publicar e distribuir seu trabalho on-line (por exemplo, em repositórios institucionais ou em sua página pessoal) a qualquer momento após o processo editorial.
Além disso, o AUTOR fica informado e consente que o HSJ possa incorporar seu artigo em bases de dados e indexadores científicos existentes ou futuros, nas condições definidas por estes a cada momento, o que envolverá, pelo menos, a possibilidade de que os titulares de esses bancos de dados podem executar as seguintes ações no artigo.
Referências
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007;356(3):213-5. https://doi.org/10.1056/NEJMp068177 DOI: https://doi.org/10.1056/NEJMp068177
Joyce T, Chirino YI, Natalia MT, Jose PC. Renal damage in the metabolic syndrome (MetSx): Disorders implicated. Eur J Pharmacol. 2018;818:554-68. https://doi.org/10.1016/j.ejphar.2017.11.032 DOI: https://doi.org/10.1016/j.ejphar.2017.11.032
Beddhu S, Filipowicz R, Wang B, Wei G, Chen X, Roy AC, et al. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Can J Kidney Health Dis. 2016;3:2054358116675343. https://doi.org/10.1177/2054358116675343 DOI: https://doi.org/10.1177/2054358116675343
Deibert P, Lutz L, Konig D, Zitta S, Meinitzer A, Vitolins MZ, Becker G, Berg A. Acute effect of a soy protein-rich meal-replacement application on renal parameters in patients with the metabolic syndrome. Asia Pac J Clin Nutr. 2011;20(4):527-34.
Meigs JB. Metabolic syndrome: in search of a clinical role. Diabetes Care. 2004;27(11):2761-3. https://doi.org/10.2337/diacare.27.11.2761. Erratum in: Diabetes Care. 2005;28(1):238. DOI: https://doi.org/10.2337/diacare.27.11.2761
Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Tai TY, et al. Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study. Diabetes Care. 2011;34(4):982-7. https://doi.org/10.2337/dc10-1718 DOI: https://doi.org/10.2337/dc10-1718
Viazzi F, Leoncini G, Grassi G, Pontremoli R. Antihypertensive treatment and renal protection: Is there a J-curve relationship? J Clin Hypertens (Greenwich). 2018;20(11):1560-1574. https://doi.org/10.1111/jch.13396 DOI: https://doi.org/10.1111/jch.13396
Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol. 2014;3(4):210-9. https://doi.org/10.5527/wjn.v3.i4.210 DOI: https://doi.org/10.5527/wjn.v3.i4.210
Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551 https://doi.org/10.1161/01.CIR.0000112379.88385.67 DOI: https://doi.org/10.1161/01.CIR.0000112379.88385.67
The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. Drzewoski J, Hanefeld M. Pharmaceuticals (Basel). 2021;14(2):122. https://doi.org/10.3390/ph14020122 DOI: https://doi.org/10.3390/ph14020122
Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. https://doi.org/10.1186/s12933-021-01366-8 DOI: https://doi.org/10.1186/s12933-021-01366-8
Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome - What is it and how should it be managed? Eur J Prev Cardiol. 2019;26(2_suppl):33-46. doi: https://doi.org/10.1177/2047487319886404 DOI: https://doi.org/10.1177/2047487319886404
Amor A, Jiménez A, Moizé V, Ibarzabal A, Flores L, Lacy AM, Vidal J. Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery. Surg Endosc. 2013;27(6):2046-51. https://doi.org/10.1007/s00464-012-2708-3 DOI: https://doi.org/10.1007/s00464-012-2708-3
Suzuki H, Shuto H, Shuto C, Ohara I, Inokuma S, Abe Y, Sukigara M. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome. Ther Adv Cardiovasc Dis. 2012;6(4):141-7. https://doi.org/10.1177/1753944712452191 DOI: https://doi.org/10.1177/1753944712452191
Park JB, Kim SA, Sung KC, Kim JY. Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study. PLoS One. 2017;12(12):e0189342. https://doi.org/10.1371/journal.pone.0189342 DOI: https://doi.org/10.1371/journal.pone.0189342
Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001;3(2):99-102. https://doi.org/10.1111/j.1524-6175.2001.00442.x DOI: https://doi.org/10.1111/j.1524-6175.2001.00442.x
Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al.; American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79-83. https://doi.org/10.2337/diacare.27.2007.S79 DOI: https://doi.org/10.2337/diacare.27.2007.S79
Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-20-01 DOI: https://doi.org/10.46658/JBIMES-20-01
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644 DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of software to support multiple systematic review types: the JBI System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc. 2019;17(1):36-43. https://doi.org/10.1097/XEB.0000000000000152 DOI: https://doi.org/10.1097/XEB.0000000000000152
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, Aromataris E, Munn Z. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494-506. https://doi.org/10.11124/JBIES-22-00430 DOI: https://doi.org/10.11124/JBIES-22-00430
Rashidbeygi E, Safabakhsh M, Delshad Aghdam S, Mohammed SH, Alizadeh S. Metabolic syndrome and its components are related to a higher risk for albuminuria and proteinuria: Evidence from a meta- analysis on 10,603,067 subjects from 57 studies. Diabetes Metab Syndr. 2019;13(1):830-843. https://doi.org/10.1016/j.dsx.2018.12.006 DOI: https://doi.org/10.1016/j.dsx.2018.12.006
Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93-104. https://doi.org/10.1038/ki.2010.531 DOI: https://doi.org/10.1038/ki.2010.531
Van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52. https://doi.org/10.1038/ki.2010.536 DOI: https://doi.org/10.1038/ki.2010.536
Guzmán A, Navarro E, Obando L, Pacheco J, Quirós K, Vásquez L, et al. Effectiveness of interventions for the reversal of a metabolic syndrome diagnosis: An update of a meta-analysis of mixed treatment comparison studies. Biomedica. 2019;39(4):647-62. https://doi.org/10.7705/biomedica.4684 DOI: https://doi.org/10.7705/biomedica.4684